MiNK Therapeutics has announced a groundbreaking development in cancer treatment with the recent publication in Nature's Oncogene, highlighting a complete and durable remission in a patient suffering from metastatic, heavily pre-treated testicular cancer. This remarkable outcome followed treatment with agenT-797, MiNK's innovative allogeneic iNKT cell therapy, administered in combination with nivolumab.

This patient's case is particularly significant because they had previously failed numerous conventional and experimental therapies, including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors like anti–PD-1, anti–CTLA-4, and anti–TIGIT. Despite this extensive treatment history and progression, the patient achieved a full clinical, radiologic, and biochemical remission, with no evidence of disease recurrence for over two years. Crucially, the treatment was remarkably well-tolerated, with no reported instances of cytokine release syndrome (CRS) or graft-versus-host disease (GVHD), which are common and serious side effects of many cell therapies. Donor iNKT cells were even detectable up to six months post-infusion, indicating a sustained presence of the therapeutic cells.

This published case adds to a growing body of clinical evidence supporting the potent potential of agenT-797 in treating solid tumors. MiNK Therapeutics previously presented data from its Phase 2 trial in second-line gastric cancer at the 2025 AACR Immuno-Oncology meeting, showing immune activation, increased tumor infiltration, and early signals of tumor control in patients who had been refractory to checkpoint inhibitors. Notably, some patients in this trial experienced extended survival beyond 12 months, an outcome rarely seen in this challenging setting. Another peer-reviewed case report in Oncogene further reinforced these findings, describing a patient with metastatic gastric cancer who achieved a 42% tumor reduction and over nine months of progression-free survival after a single agenT-797 infusion with nivolumab.

These combined findings underscore agenT-797's ability to re-engineer the tumor microenvironment and deliver durable clinical activity even in cancers that have proven resistant to other immunotherapies. MiNK Therapeutics continues to advance its clinical program, with the Phase 2 trial in gastric cancer (NCT06251973) actively enrolling and additional readouts anticipated in the coming months. MiNK's proprietary BEAT® protein platform enables the development of these unique trispecific antibodies, positioning agenT-797 as a promising new frontier in the treatment of challenging cancers.